
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics has demonstrated strong financial performance, with its Integrity product line achieving over 100% revenue growth forecasted for 2025 compared to 2024. The company's regenerative solutions business, particularly driven by the Integrity patch, reported a notable 41% growth in the recent quarter, contributing positively to overall revenue. Additionally, international osteoarthritis pain revenue showed a robust 21% increase year-over-year, indicating a favorable market response and expanding global presence.
Bears say
Anika Therapeutics Inc reported a revenue decline of 5.9% to $27.8 million in the latest period, indicating ongoing financial challenges as it excludes recent divestitures. The company's gross margin fell to 56%, below expectations, mainly due to persistent production yield issues, which have also impacted international osteoarthritis pain revenue, leading to a 10% decrease year-over-year. Over the last 12-18 months, the company has faced a series of adverse developments, resulting in a negative outlook for its stock performance.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares